The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GTBP | -69.53% | -99.58% | -66.54% | -100% |
| S&P | +15.66% | +85.04% | +13.1% | +4,015% |
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.
No news articles found for GT Biopharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $2.09M | -59.6% |
| Market Cap / Employee | $2.09M | 0.0% |
| Employees | 1 | -50.0% |
| Net Income | -$3,114.00K | 8.7% |
| EBITDA | -$3,382.00K | 6.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.62M | 72.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -164.22% | -56.4% |
| Return On Invested Capital | 68.29% | 117.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3,677.00K | -34.3% |
| Operating Free Cash Flow | -$3,677.00K | -34.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.25 | -2.87 | -9.26 | 0.67 | -28.35% |
| Price to Tangible Book Value | 3.25 | -2.87 | -9.26 | 0.67 | -28.35% |
| Enterprise Value to EBITDA | -0.74 | -1.34 | -4.34 | 0.09 | -75.64% |
| Return on Equity | -453.4% | -538.9% | -182.0% | -357.0% | 74.93% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
